Is Amaros Co., Ltd Safe? FDA Warning Letter Review (2017)
Compiled by the Supplement Safety Data Team | Sourced from Official FDA Records on December 13, 2017
Executive Summary
The FDA issued a warning letter to Amaros Co., Ltd on December 13, 2017 citing cgmp violations. The letter was issued by Center for Drug Evaluation and Research.
Detailed Analysis
False Claims and Regulatory Violations
The FDA identified regulatory violations in Amaros Co., Ltd's operations or product claims.
Potential Health Risks
Consumers should be aware of potential risks associated with products from Amaros Co., Ltd.
Regulatory Context
Written procedures establishing your supplier and contractor qualification, selection, and oversight program, including procedures to ensure compliance with drug CGMP at all stages of manufacturing processing packing, or holding.
Key Entities Identified
Frequently Asked Questions
- What did the FDA find wrong with Amaros Co., Ltd?
- The FDA issued a warning letter citing cgmp violations related to their products or manufacturing practices.
- Are Amaros Co., Ltd products safe to use?
- Based on the FDA's findings, consumers should exercise caution. The company was found to have cgmp violations that may affect product safety.
- What should I do if I've used Amaros Co., Ltd products?
- If you have used products from Amaros Co., Ltd and experience any adverse effects, contact your healthcare provider immediately. You can also report adverse events to the FDA's MedWatch program.
Source Document
This report is based on an official FDA warning letter. The original document is a public record.
View Original FDA Warning Letter